AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

February 28, 2023

https://www.globenewswire.com/news-release/2023/02/28/2617118/29489/en/AIM-ImmunoTech-Announces-Phase-2-Study-of-Ampligen-for-the-Treatment-of-Pancreatic-Cancer-is-Open-and-Recruiting-Patients.html

OCALA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced that the AMP-270 Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (“LAPC”) has opened its first clinical site and has begun recruiting patients.

Read more at globenewswire.com

Related news for (AIM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.